The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
// Kevin S. Quackenbush 1 , Stacey Bagby 1 , Wai Meng Tai 1, 2 , Wells A. Messersmith 1 , Anna Schreiber 1 , Justin Greene 1 , Jihye Kim 1 , Guoliang Wang 1 , Alicia Purkey 1 , Todd M. Pitts 1 , Anna Nguyen 1 , Dexiang Gao 1 , Patrick Blatchford 1 , Anna Capasso 1 , Alwin G. Schuller 3 , S. Gail Eckhardt 1 , John J. Arcaroli 1 1 Division of Medical Oncology, University of Colorado Denver and University of Colorado Cancer Center, Denver, CO, USA 2 Division of Medical Oncology, National Cancer Centre Singapore, Singapore 3 AstraZeneca R & D Boston, Massachusetts, Waltham, Massachusetts, MA, USA Correspondence to: John J. Arcaroli, email: john.arcaroli@ucdenver.edu Keywords: CRC, WNT, IRN, NuMA, PDTX Received: December 30, 2015 Accepted: February 28, 2016 Published: April 07, 2016 ABSTRACT Background: Dysregulation of the canonical Wnt signaling pathway has been implicated in colorectal cancer (CRC) development as well as incipient stages of malignant transformation. In this study, we investigated the antitumor effects of AZ1366 (a novel tankyrase inhibitor) as a single agent and in combination with irinotecan in our patient derived CRC explant xenograft models. Results: Six out of 18 CRC explants displayed a significant growth reduction to AZ1366. There was one CRC explant (CRC040) that reached the threshold of sensitivity (TGII ≤ 20%) in this study. In addition, the combination of AZ1366 + irinotecan demonstrated efficacy in 4 out of 18 CRC explants. Treatment effects on the WNT pathway revealed that tankyrase inhibition was ineffective at reducing WNT dependent signaling. However, the anti-tumor effects observed in this study were likely a result of alternative tankyrase effects whereby tankyrase inhibition reduced NuMA levels. Materials and Methods: Eighteen CRC explants were treated with AZ1366 single agent or in combination for 28 days and treatment responses were assessed. Pharmacokinetic (AZ1366 drug concentrations) and pharmacodynamic effects (Axin2 levels) were investigated over 48 hours. Immunohistochemistry of nuclear β-catenin levels as well as western blot was employed to examine the treatment effects on the WNT pathway as well as NuMA. Conclusions: Combination AZ1366 and irinotecan achieved greater anti-tumor effects compared to monotherapy. Activity was limited to CRC explants that displayed irinotecan resistance and increased protein levels of tankyrase and NuMA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
Self-citationThe Roles of APC and Axin Derived from Experimental and Theoretical Analysis of the Wnt Pathway
Lee, E., Salic, A., Krüger, R., Heinrich, R., & Kirschner, M. W. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000010 · Cited by 708
β-Catenin destruction complex: insights and questions from a structural perspective
Kimelman, D., & Xu, W. (2006) · Oncogene · doi:10.1038/sj.onc.1210055 · Cited by 628
Gurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614 · cited 1×
“A study by Gurney and colleagues [31] also showed combination effects of OMP-18R5 (an anti-Frizzled receptor antibody) + irinotecan in a CRC PDTX model.”
BackgroundColorectal cancer and genetic alterations in the Wnt pathway
Segditsas, S., & Tomlinson, I. (2006) · Oncogene · doi:10.1038/sj.onc.1210059 · Cited by 591
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
Lau, T., Chan, E., Callow, M., Waaler, J., Boggs, J., Blake, R. A., Magnuson, S., Sambrone, A., Schutten, M., Firestein, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4562 · Cited by 316 · cited 6×
“com/oncotarget been evaluated in preclinical models of CRC and have demonstrated limited activity [12, 16, 27].”
BackgroundInfluential
Cited by
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
Katoh, M. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4129 · Cited by 465
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
“…which target β-catenin, AXIN, APC, and other components involved in pathway activation; (3) nuclear level inhibitors, which modulate the transcription of transcription of target genes, such as transcriptional co-factors; and (4) inhibitors that interact with other signaling pathways [315].”
BackgroundWNT Signaling in Cardiac and Vascular Disease
Foulquier, S., Daskalopoulos, E. P., Lluri, G., Hermans, K. C. M., Deb, A., & Blankesteijn, W. M. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.013896 · Cited by 347
β-Catenin signaling in hepatocellular carcinoma
Xu, C., Xu, Z., Zhang, Y., Evert, M., Calvisi, D. F., & Chen, X. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154515 · Cited by 305
Metadata
- Authors
- Quackenbush, K. S., Bagby, S., Tai, W. M., Messersmith, W. A., Schreiber, A., Greene, J., Kim, J., Wang, G., Purkey, A., Pitts, T. M., Nguyen, A., Gao, D., Blatchford, P., Capasso, A., Schuller, A. G., Eckhardt, S. G., & Arcaroli, J. J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-04-07
- Volume
- 7
- Issue
- 19
- Pages
- 28273-28285
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2330572103
- Cited by
- 43
- References
- 7
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.